FDA approves Jazz Pharma's leukemia drug

The Food and Drug Administration on Aug. 3 approved Jazz Pharmaceuticals' acute myeloid leukemia treatment Vyxeos.

Here are three things to know.

1. Vyxeos is a fixed-combination therapy containing two chemotherapy drugs.
   
   

2. The drug is intended to treat adults with two types of high-risk AML.
   
   

3. In a recent clinical trial, patients taking Vyxeos had a median overall survival of 9.56 months, compared to 5.95 months for those receiving the two chemotherapy drugs separately.
   
   

More articles on supply chain:

Device recalls fall in Q2, drug recalls rise: 10 report findings
Woman sues CVS over generic drug co-pay 'clawbacks'
Fujifilm recalls duodenoscopes over infection risk